Venus Remedies Ltd

Venus Remedies Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Venus Remedies Ltd

₹ 530 -0.39%
01 Aug - close price
venusremedies.com BSE: 526953 NSE: VENUSREM
About

Incorporated in 1989, Venus Remedies
Ltd is a research based pharmaceutical company and an injectable manufacturer[1]

Key Points

Business Overview:[1][2]
VSR is one of the largest manufacturers of meropenem antibiotics and emerging player in AMR drug in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin
& wound care. Company has 1040+ marketing authorizations globally, 135+ patents and 180+ product basket which includes formulations such as injectables,
tablets, and topical preparations

Website BSE NSE - BE
  • Market Cap ₹ 708 Cr.
  • Current Price ₹ 530
  • High / Low ₹ 568 / 270
  • Stock P/E 13.5
  • Book Value ₹ 441
  • Dividend Yield 0.00 %
  • ROCE 11.9 %
  • ROE 8.10 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 6.87% over last 3 years.
  • Earnings include an other income of Rs.37.1 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
155 125 110 149 99 170 131 175 106 167 173 194 132
137 110 103 128 85 157 118 154 92 157 150 171 119
Operating Profit 18 15 7 21 13 13 13 21 14 10 23 23 13
OPM % 12% 12% 6% 14% 14% 8% 10% 12% 13% 6% 13% 12% 10%
1 2 4 3 2 3 2 4 2 11 12 7 8
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 8 9 7 8 7 6 6 6 6 6 5 4 6
Profit before tax 12 8 4 16 8 10 9 19 10 15 29 25 15
Tax % 8% 5% 32% 53% 47% 45% 10% 36% 56% 37% 18% 40% 20%
11 8 3 8 4 5 8 13 4 9 24 15 12
EPS in Rs 8.30 5.78 1.95 5.64 3.25 4.08 6.13 9.36 3.33 6.93 18.01 11.06 8.75
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
515 443 392 375 355 299 316 511 574 534 570 631 665
382 356 312 328 312 265 273 464 505 473 509 561 597
Operating Profit 133 87 80 47 44 34 43 47 69 62 61 70 68
OPM % 26% 20% 20% 13% 12% 11% 14% 9% 12% 12% 11% 11% 10%
0 1 1 1 1 -4 -5 41 8 10 11 31 37
Interest 29 41 37 34 35 25 13 13 0 0 0 0 0
Depreciation 39 45 40 39 33 33 31 34 33 31 26 22 22
Profit before tax 66 2 3 -25 -23 -28 -6 41 45 40 47 79 84
Tax % 7% -123% 60% -18% 13% -4% 31% -32% -10% 28% 35% 34%
61 5 1 -20 -27 -27 -8 54 49 29 30 53 60
EPS in Rs 53.27 3.98 1.05 -16.40 -21.54 -21.97 -6.67 43.97 36.65 21.67 22.82 39.32 44.75
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 4%
5 Years: 15%
3 Years: 3%
TTM: 14%
Compounded Profit Growth
10 Years: 26%
5 Years: 103%
3 Years: -3%
TTM: 71%
Stock Price CAGR
10 Years: 13%
5 Years: 45%
3 Years: 34%
1 Year: 26%
Return on Equity
10 Years: 3%
5 Years: 8%
3 Years: 7%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 11 11 11 12 12 12 12 12 13 13 13 13
Reserves 456 455 433 382 356 329 320 388 436 465 495 576
288 319 327 308 302 294 216 48 39 39 39 0
81 60 63 65 78 97 96 99 91 92 94 124
Total Liabilities 836 845 834 767 748 732 644 547 579 609 641 713
416 426 434 389 370 347 271 244 225 200 203 214
CWIP 68 78 80 66 65 65 25 25 25 26 21 26
Investments 29 29 29 29 0 0 0 0 0 20 19 84
323 312 291 283 314 320 348 277 329 363 398 388
Total Assets 836 845 834 767 748 732 644 547 579 609 641 713

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
53 67 42 62 52 44 78 132 41 28 35 83
-94 -67 3 -18 -11 -11 -5 56 -17 -51 -7 -76
39 -0 -46 -44 -40 -35 -72 -162 -9 0 0 0
Net Cash Flow -2 -1 -0 0 0 -2 1 26 15 -23 28 7

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 44 49 50 41 45 38 34 12 19 58 57 57
Inventory Days 173 189 210 230 242 283 282 130 121 123 122 98
Days Payable 34 35 36 50 48 67 70 74 48 53 54 67
Cash Conversion Cycle 183 203 223 220 239 254 246 67 93 129 126 88
Working Capital Days 40 54 73 52 23 -3 77 68 84 118 129 97
ROCE % 13% 6% 5% 1% 2% 1% 3% 6% 10% 8% 9% 12%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76%
1.13% 1.07% 1.00% 0.98% 1.03% 1.59% 1.48% 1.06% 1.18% 1.11% 1.34% 2.25%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.11%
57.11% 57.19% 57.26% 57.26% 57.21% 56.65% 56.76% 57.17% 57.06% 57.13% 56.90% 55.89%
No. of Shareholders 22,01522,24321,71920,49819,26719,56019,91319,61419,55719,77119,98219,307

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings